Results 271 to 280 of about 119,184 (308)
Some of the next articles are maybe not open access.

Hepatitis B e Antigen (HBeAg)

1985
A third antigenic specificity associated with HBV infection, designated as e antigen or HBeAg, was found in the sera of some individuals with acute or chronic hepatitis as detected by immunodiffusion (51, 52, 459). The screening of HBsAg positive sera from hemodialysis patients for this antigen revealed a close correlation between the presence of e ...
openaire   +1 more source

Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients

Liver International, 2017
AbstractBackgroundHepatitis B surface antigen (HBsAg) seroconversion in HBeAg −ve chronic hepatitis B (CHB) infection is rare, possibly due to poor antigen processing and impaired humoral response. We investigated the role of dendritic cells (DCs), T follicular helper (TFH) cells and plasma B cells in seroconversion.MethodsHBeAg −ve (n=135) CHB ...
Ashish Kumar Vyas   +3 more
openaire   +2 more sources

Quantitative Hepatitis B e Antigen: A Better Predictor of Hepatitis B Virus DNA than Quantitative Hepatitis B Surface Antigen

Clinical Laboratory, 2018
Hepatitis B surface antigen is usually secreted by infected hepatocytes in the form of subviral particles rather than infectious virions, while the hepatitis B e antigen originates from the core gene and is modified and secreted by hepatocytes into the circulation and functions as a marker of active viral replication.
Hudu, Shuaibu A.   +7 more
openaire   +2 more sources

Hepatitis B virus DNA prediction rules for hepatitis B e antigen–negative chronic hepatitis B

Hepatology, 2007
Abstract After hepatitis B e antigen (HBeAg) seroconversion, hepatitis B may become inactive or progress to HBeAg-negative hepatitis with persistent or intermittent alanine aminotransferase (ALT) elevation.
Jordan J, Feld   +5 more
openaire   +2 more sources

Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine

Journal of Hepatology, 2003
The advent of lamivudine (LAM) has provided an alternative also to the therapy of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB); management of this disease with alpha-interferon (IFN) has been problematic because of the poor response and high relapse rate of short-term therapies and because of the important side effects associated ...
RIZZETTO, Mario, MARZANO A, LAGGET M.
openaire   +3 more sources

Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment

Seminars in Liver Disease, 2006
Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B evolves in the natural history of chronic hepatitis B virus (HBV) infection linked with selection of nonproducing HBeAg but replication-competent HBV mutants, and may have a potentially severe and progressive course.
Stephanos J, Hadziyannis   +1 more
openaire   +2 more sources

e-Antigen bei akuter Hepatitis B

1977
Das Hepatitis B-Virus (HBV), identisch mit den sog. Dane-SubPartikeln, besitzt 2 immunologisch differente Antigene, das Hullantigen (HBsAG) und das Kernantigen (HBcAG). Zusatzlich ist seit 1972 ein drittes Antigen in Zusammenhang mit der B-Virus-Infektion bekannt, das sog.
K. P. Maier, H. Berthold, G. Lönngren
openaire   +1 more source

Hepatitis B e‐antigen negative chronic hepatitis B

Journal of Gastroenterology and Hepatology, 2002
S K, Sarin, S K, Satapathy, R, Chauhan
openaire   +2 more sources

Profile of hepatitis B e antigen-negative chronic hepatitis B.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2002
Although chronic hepatitis B occurs in hepatitis B e antigen (HBeAg)-negative patients, its prevalence and clinical significance are not known.To determine the prevalence and profile of HBeAg-negative chronic hepatitis B virus (HBV) infection.A retrospective analysis of 363 consecutive patients (mean age 36 y; 288 men) with chronic HBV infection was ...
D N, Amarapurkar   +5 more
openaire   +1 more source

Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients

Expert Opinion on Investigational Drugs, 2007
The primary goal of treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB) is potent and durable suppression of hepatitis B virus (HBV) replication. It results in biochemical and histological remission of CHB and is the prerequisite for the prevention of cirrhosis, its life-threatening complications and ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy